Chemical formula: C₁₇H₂₆ClNO Molecular mass: 295.85 g/mol
Pitolisant interacts in the following cases:
In two dedicated QT studies, supra-therapeutic doses of pitolisant (6-12-times the therapeutic dose, that is 108 mg to 216 mg) produced mild to moderate prolongation of QTc interval (10-13 ms). Patients with cardiac disease, hypertension, at risk of major adverse cardiovascular events (MACE), co-medicated with other QT-prolonging medicinal products or known to increase the risk of repolarization disorders should be carefully monitored.
Pitolisant may be a clinically relevant inhibitor of OCT1 based on in vitro data and a clinically relevant interaction may occur with substrates of OCT1 (e.g. metformin).
Even if the clinical relevance of this effect is not established, caution is advised when pitolisant is administered with a substrate of OCT1 (e.g. metformin (biguanides)).
CYP2D6 inhibitors will most likely have an effect on the pharmacokinetics of pitolisant in subjects that are CYP2D6 intermediate, extensive metabolizers or ultra-rapid metabolizers and taking no CYP3A inducers, but not in subjects that are CYP2D6 poor metabolizers or intermediate, extensive metabolizers or CYP2D6 ultra-rapid metabolizers and taking CYP3A inducers. A dosage adjustment during the combination could eventually be considered depending on individual response and tolerance.
Co-administration of pitolisant with paroxetine significantly increases pitolisant mean Cmax and AUC0—72h ratio about 1.5 fold and 2 fold, respectively. Given the 2-fold increase of pitolisant exposure, its coadministration with CYP2D6 inhibitors (e.g. paroxetine, fluoxetine, venlafaxine, duloxetine, bupropion, quinidine, terbinafine, cinacalcet) should be done with caution.
CYP3A inducers will most likely have an effect on the pharmacokinetics of pitolisant in CYP2D6 poor metabolizers and CYP2D6 ultra-rapid metabolizers and their effect in these populations is currently unknown. A clinical monitoring should be made when both active substances are combined and, eventually a dosage adjustment during the combination and one week after the inducer treatment.
Co-administration of pitolisant with rifampicin in multiple doses significantly decreases pitolisant mean Cmax and AUC ratio about 0.6 fold and 0.5 fold, respectively. Therefore, co-administration of pitolisant with potent CYP3A4 inducers (e.g. rifampicin, phenobarbital, carbamazepine, phenytoin) should be done with caution. With St John's Wort (Hypericum perforatum), due to its strong CYP3A4 inducing effect, caution should be exercised when taken concurrently with pitolisant.
CYP3A inhibitors will most likely have an effect on the pharmacokinetic of pitolisant in CYP2D6 poor metabolizers and their effect in this population is currently unknown. The combination of pitolisant with grapefruit juice and itraconazole was evaluated in healthy volunteers. No clinically relevant pharmacokinetic drug-drug interaction was evidenced with any of these combinations. However, based on the biotransformation pathway caution should be exercised in subjects that are CYP2D6 poor metabolizers due to a significant decrease in clearance and an increase in exposure.
With CYP3A4, CYP2C (e.g. repaglinide, phenytoin, warfarin), P-gp (e.g. dabigatran, digoxin) and UGT (e.g. morphine, paracetamol, irinotecan) substrates, caution should be made with a clinical monitoring of their efficacy.
In patients with renal impairment, the maximum daily dose should be 18 mg.
In patients with moderate hepatic impairment (Child-Pugh B) two weeks after initiation of treatment, the daily dose can be increased without exceeding a maximal dose of 18 mg.
Pitolisant might decrease the exposure to oral contraceptives and an additional further reliable contraceptive method should be used.
Pitolisant decreases the olanzapine exposure by 0.3 fold.
In a clinical multiple dose study, the combination of pitolisant with probenecid decreases the AUC of pitolisant by about 0.7 fold. The underlying mechanism is unknown. A dosage adjustment during the combination could eventually be considered depending on individual response and tolerance.
Pitolisant should be administered with caution in patients with severe obesity or severe anorexia. In case of significant weight change, treatment should be re-evaluated by the physician.
Gastric disorders reactions have been reported with pitolisant, therefore it should be administered with caution in patients with acid related gastric disorders or when co-administered with gastric irritants such as corticosteroids or NSAID.
By comparison to CYP2D6 extensive metabolizers, higher systemic exposure (up to 3 fold) is observed in CYP2D6 poor metabolizers and lower exposure (by 0.8-fold) is observed in CYP2D6 ultra-rapid metabolizers. No differences in systemic exposure is observed between CYP2D6 extensive and intermediate metabolizers.
In the up-titration scheme, dose increment should take into account the higher exposure in CYP2D6 poor metabolizers, and a dosage adjustment in patients with known poor CYP2D6 metabolizer genotype could be considered depending on individual response and tolerance. Furthermore, no dose recommendation can currently be given for CYP2D6 ultra-rapid metabolizers taking a CYP3A inducer, because the PK is currently unknown in this subpopulation.
Pitolisant should be administered with caution in patients with history of psychiatric disorders such as severe anxiety or severe depression with suicidal ideation risk. Suicidal ideation has been reported in patients with psychiatric history treated with pitolisant.
Convulsions were reported at high doses in animal models. In clinical studies, one epilepsy aggravation was reported in one epileptic patient. Caution should be taken for patients with severe epilepsy.
There are no or limited amount of data from the use of pitolisant in pregnant women. Studies in animals have shown reproductive toxicity, including teratogenicity. In rats, pitolisant/metabolites were shown to cross the placenta.
Pitolisant should not be used during pregnancy unless the potential benefit outweighs the potential risk for foetus.
Animal study has shown excretion of pitolisant/metabolites in milk. Therefore, breastfeeding is contraindicated during treatment with pitolisant.
Women of childbearing potential have to use effective contraception during treatment and at least up to 21 days after treatment discontinuation (based on pitolisant/metabolites half-life). Pitolisant/metabolites may reduce the effectiveness of hormonal contraceptives. Therefore, an alternative method of effective contraception should be used if the woman is using hormonal contraceptives.
Study in animals has shown effects on semen parameters, without a significant impact on reproductive performance in males and reduction on the percentage of live foetuses in treated females.
Pitolisant has minor influence on the ability to drive and use machines.
Patients with abnormal levels of sleepiness who take pitolisant should be advised that their level of wakefulness may not return to normal. Patients with excessive daytime sleepiness, including those taking pitolisant should be frequently reassessed for their degree of sleepiness and, if appropriate, advised to avoid driving or any other potentially dangerous activity.
The most frequent adverse reactions are headache 9.5%, insomnia (all types) 8.0%, anxiety 2.7%, nausea 2.3%, abdominal pain 1.9% and vertigo 1.7%.
The following adverse reactions have been reported with pitolisant during clinical studies are listed below as MedDRA preferred term by system organ class and frequency; frequencies are defined as: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000); within each frequency group, adverse reactions are presented in order of decreasing seriousness:
| Common | Uncommon | |
|---|---|---|
| Infections and infestations | Herpes zoster Viral upper respiratory tract infection | |
| Blood and lymphatic system disorders | Alanine aminotransferase increased Blood cholesterol increased Blood pressure increased Blood triglycerides increased Hepatic enzyme increased Transaminase increased | |
| Metabolism and nutrition disorders | Alcohol intolerance Increased appetite Hypoglycaemia Weight decreased Weight increased | |
| Psychiatric disorders | Insomnia (all types) Anxiety disorders Sleep disorders | Confusional arousal Depressed mood disorders and disturbances Fear Irritability Nervousness disorders Libido disorders Panic reaction Withdrawal syndrome |
| Nervous system disorders | Headache | Circadian rhythm sleep disorder Dizziness Dysgeusia Psychomotor hyperactivity Migraine Sleep paralysis Hypotonia |
| Eye disorders | Swelling of eyelid Dry eye Photopsia | |
| Ear and labyrinth disorders | Vertigo | Tinnitus |
| Cardiac disorders | Atrioventricular block first degree Palpitations Tachycardia Ventricular extrasystoles Electrocardiogram QT prolonged Heart rate increased | |
| Vascular disorders | Hot flush Hypertension Hypertensive crisis | |
| Respiratory, thoracic and mediastinal disorders | Yawning Cough Nocturnal dyspnoea | |
| Gastrointestinal disorders | Nausea/vomiting Abdominal pain and discomfort | Diarrhoea Constipation Dry mouth Enterocolitis Faeces discoloured Gastrointestinal disorders Breath odour Flatulence Rectal haemorrhage Salivary hypersecretion |
| Skin and subcutaneous tissue disorders | Rash Hyperhidrosis Pruritus Erythema Cold sweat Night sweats Solar dermatitis | |
| Musculoskeletal and connective tissue disorders | Limb discomfort Muscle spasms Myalgia Arthralgia Tendonitis | |
| Renal and urinary disorders | Pollakiuria | |
| General disorders and administration site conditions | Pain and Discomfort Asthenia Pyrexia Thirst Oedema peripheral |
During clinical studies in OSA indication, episodes of headache and insomnia have been reported (9.5% and 8.0%) more frequently in women (headache and insomnia) and in elderly (insomnia) patients. Most of these adverse reactions were mild to moderate. Dosing should be adjusted accordingly.
Gastric disorders presumably caused by hyperacidity have been reported during clinical studies in 3.5% of the patients receiving pitolisant. Higher rates of nausea are reported in women. These effects were mostly mild to moderate. If they persist, a corrective treatment with proton pump inhibitor could be initiated.
Headache, insomnia, nausea and anxiety have been reported in higher rates in patients with low/normal BMI. Dosing should be adjusted accordingly.
The most frequent adverse drug reactions (ADRs) reported with pitolisant in adult patients were insomnia (8.4%), headache (7.7%), nausea (4.8%), anxiety (2.1%), irritability (1.8%), dizziness (1.4%), depression (1.3%), tremor (1.2%), sleep disorders (1.1%), fatigue (1.1%), vomiting (1.0%), vertigo (1.0%), dyspepsia (1.0%), weight increase (0.9%), abdominal pain upper (0.9%). The most serious ADRs are abnormal weight decrease (0.09%) and abortion spontaneous (0.09%).
The following adverse reactions have been reported with pitolisant during clinical studies in narcolepsy and other indications and are listed below as MedDRA preferred term by system organ class and frequency; frequencies are defined as: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000); within each frequency group, adverse reactions are presented in order of decreasing seriousness:
| MedDRA System Organ Class | Common | Uncommon | Rare |
|---|---|---|---|
| Metabolism and nutrition disorders | Decreased appetite Increased appetite Fluid retention | Anorexia Hyperphagia Appetite disorder | |
| Psychiatric disorders | Insomnia Anxiety Irritability Depression Sleep disorder | Agitation Hallucination Hallucination visual, auditory Affect lability Abnormal dreams Dyssomnia Middle insomnia Initial insomnia Terminal insomnia Nervousness Tension Apathy Nightmare Restlessness Panic Attack Libido decreased Libido increased Suicidal ideation | Abnormal behaviour Confusional state Depressed mood Excitability Obsessive thoughts Dysphoria Hypnopompic hallucination Depressive symptom Hypnagogic hallucination Mental impairment |
| Nervous system disorders | Headache Dizziness Tremor | Dyskinesia Balance disorder Cataplexy Disturbance in attention Dystonia On and off phenomenon Hypersomnia Migraine Psychomotor hyperactivity Restless Legs Syndrome Somnolence Epilepsy Bradykinesia Paresthesia | Loss of consciousness Tension headache Memory impairment Poor sleep quality |
| Eye disorders | Visual acuity reduced Blepharospasm | ||
| Ear and labyrinth disorders | Vertigo | Tinnitus | |
| Cardiac disorders | Extrasystoles Bradycardia | ||
| Vascular disorders | Hypertension Hypotension Hot flush | ||
| Respiratory, thoracic and mediastinal disorders | Yawning | ||
| Gastrointestinal disorders | Nausea Vomiting Dyspepsia | Dry mouth Abdominal pain Diarrhoea Abdominal discomfort Abdominal pain upper Constipation Gastroesophageal reflux disease Gastritis Gastrointestinal pain Hyperacidity Paraesthesia oral Stomach discomfort | Abdominal distension Dysphagia Flatulence Odynophagia Enterocolitis |
| Skin and subcutaneous tissue disorders | Erythema Pruritus Rash Hyperhidrosis Sweating | Toxic skin eruption Photosensitivity | |
| Musculoskeletal and connective tissue disorders | Arthralgia Back pain Muscle rigidity Muscular weakness Musculoskeletal pain Myalgia Pain in extremity | Neck pain Musculoskeletal chest pain | |
| Renal and urinary disorders | Pollakiuria | ||
| Pregnancy, puerperium and perinatal conditions | Abortion spontaneous | ||
| Reproductive system and breast disorders | Metrorrhagia | ||
| General disorders and administration site conditions | Fatigue | Asthenia Chest Pain Feeling Abnormal Malaise Oedema Peripheral oedema | Pain Night sweats Sense of oppression |
| Investigations | Weight increased Weight decreased Hepatic enzymes increased Electrocardiogram QT prolonged Heart rate increased Gamma- glutamyltransferase increased | Creatine phosphokinase increased General physical condition abnormal Electrocardiogram repolarisation abnormality Electrocardiogram T wave inversion |
During clinical studies, episodes of headache and insomnia have been reported (7.7% to 8.4%). Most of these adverse reactions were mild to moderate. If symptoms persist a reduced daily dose or discontinuation should be considered.
Gastric disorders caused by hyperacidity have been reported during clinical studies in 3.5% of the patients receiving pitolisant. These effects were mostly mild to moderate. If they persist a corrective treatment with proton pump inhibitor could be initiated.
The paediatric population has been studied in a double-blind multicentre randomized placebo- controlled trial; a total of 73 children and adolescents with narcolepsy with or without cataplexy were treated with pitolisant for 8 weeks. Frequency, type and severity of adverse reactions in children and adolescents were similar to that of adults. The most frequent related adverse drug reactions (ADRs) reported in this population were headache (11%), insomnia (5.5%), hypertension (2.7%).
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.